Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant

Description

The purpose of the study is to evaluate fetal, maternal, and infant outcomes through 12 months of age.

Conditions

Migraine

Talk to us

Study Overview

On this page

Study Details

Study overview

The purpose of the study is to evaluate fetal, maternal, and infant outcomes through 12 months of age.

A Prospective, Registry-based, Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant: The Migraine Observational Nurtec Pregnancy Registry (MONITOR)

Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant

Condition
Migraine
Intervention / Treatment

-

Contacts and Locations

Morrisville

PPD, Morrisville, North Carolina, United States, 27560

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Pregnant women with migraine exposed to rimegepant: a diagnosis of migraine and at least 1 dose of rimegepant during pregnancy or just prior to pregnancy (up to 3 days prior to conception)
  • * Pregnant women with migraine unexposed to rimegepant: a diagnosis of migraine and no exposure to Rimegepant before or during pregnancy

Ages Eligible for Study

0 Years to

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

Pfizer,

Pfizer CT.gov Call Center, STUDY_DIRECTOR, Pfizer

Study Record Dates

2034-04-30